22 related articles for article (PubMed ID: 16222148)
1. Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies.
Zaki M; Hairat S; Aazam ES
RSC Adv; 2019 Jan; 9(6):3239-3278. PubMed ID: 35518979
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and cytotoxicity studies of titanocene C analogues.
Hogan M; Claffey J; Fitzpatrick E; Hickey T; Pampillón C; Tacke M
Met Based Drugs; 2008; 2008():754358. PubMed ID: 18274663
[TBL] [Abstract][Full Text] [Related]
3. Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo.
Bannon JH; Fichtner I; O'Neill A; Pampillón C; Sweeney NJ; Strohfeldt K; Watson RW; Tacke M; Mc Gee MM
Br J Cancer; 2007 Nov; 97(9):1234-41. PubMed ID: 17923871
[TBL] [Abstract][Full Text] [Related]
4. Dimethylamino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs: synthesis and cytotoxicity studies.
Hickey T; Claffey J; Fitzpatrick E; Hogan M; Pampillón C; Tacke M
Invest New Drugs; 2007 Oct; 25(5):425-33. PubMed ID: 17516024
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative activity of Titanocene Y against tumor colony-forming units.
Oberschmidt O; Hanauske AR; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):317-21. PubMed ID: 17264765
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.
Beckhove P; Oberschmidt O; Hanauske AR; Pampillón C; Schirrmacher V; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):311-5. PubMed ID: 17264764
[TBL] [Abstract][Full Text] [Related]
8. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of 17 beta-[N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-L-alanyl]-5 alpha-dihydrotestosterone (E91) against tumour colony forming units and haematopoietic progenitor cells.
Rank P; Peter R; Depenbrock H; Eisenbrand G; Schmid P; Pitzl H; Hanauske AR
Eur J Cancer; 1999 Jun; 35(6):1009-13. PubMed ID: 10533486
[TBL] [Abstract][Full Text] [Related]
10. Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units.
Oberschmidt O; Hanauske AR; Rehmann FJ; Strohfeldt K; Sweeney N; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1071-3. PubMed ID: 16222148
[TBL] [Abstract][Full Text] [Related]
11. Coordination Complexes of Titanium(IV) for Anticancer Therapy.
Tshuva EY; Miller M
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394027
[TBL] [Abstract][Full Text] [Related]
12. Prediction of response to cancer chemotherapy.
Sarosdy MF; Von Hoff DD
Drugs; 1983 Nov; 26(5):454-9. PubMed ID: 6357700
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
